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Abstract
Summary The COVID-19 pandemic, and its management, is markedly impacting the management of osteoporosis as judged by
access to online FRAX fracture risk assessments. Globally, access was 58% lower in April than in February 2020. Strategies to
improve osteoporosis care, with greater use of fracture risk assessments, offer a partial solution.
Introduction The COVID-19 pandemic is having a significant detrimental impact on the management of chronic diseases
including osteoporosis. We have quantified the global impact by examining changes in the usage of online FRAX fracture risk
assessments before and after the declaration of the pandemic (11 March 2020).
Methods The study comprised a retrospective analysis using GoogleAnalytics data on daily sessions on the FRAX® website
(www.sheffield.ac.uk/FRAX) from November 2019 to April 2020 (main analysis period February–April 2020), and the geo-
graphical source of that activity.
Results Over February–April 2020, the FRAX website recorded 460,495 sessions from 184 countries, with 210,656 sessions in
February alone. InMarch and April, the number of sessions fell by 23.1% and 58.3% respectively, a pattern not observed over the
same period in 2019. There were smaller reductions in Asia than elsewhere, partly related to earlier and less-marked nadirs in
some countries (China, Taiwan, Hong Kong, South Korea and Vietnam). In Europe, the majority of countries (24/31, 77.4%)
reduced usage by at least 50% in April. Seven countries showed smaller reductions (range − 2.85 to − 44.1%) including Poland,
Slovakia, Czech Republic, Germany, Norway, Sweden and Finland. There was no significant relationship between the reduction
in FRAX usage and measures of disease burden such as COVID-attributed deaths per million of the population.
Conclusion This study documents a marked global impact of the COVID-19 pandemic on the management of osteoporosis as
reflected by FRAX online fracture risk assessments. The analysis suggests that impact may relate to the societal and healthcare
measures taken to ameliorate the pandemic.
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Introduction
At the end of December 2019, a cluster of cases of pneu-
monia were reported by Wuhan Municipal Health
Commission in China (https://www.who.int/news-room/
detail/27-04-2020-who-timeline%2D%2D-covid-19). The
outbreak eventually gave rise to the COVID-19 pandemic
caused by the severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2). While some countries appeared to
control and minimise virus transmission, in many others
the number of cases and, sadly, the number of deaths
threatened to overwhelm healthcare and social systems.
The fear that the same might happen elsewhere led to
political, social and healthcare decisions to try to mitigate
the impact, efforts which were spurred on by the declara-
tion of a pandemic by WHO on 11 March 2020. While
acknowledged as appropriate and necessary, it was widely
recognised that the focus on COVID-19 would almost
certainly lead to negative effects on the management of
other diseases, particularly chronic non-communicable
diseases (NCD), which frequently provided the greatest
burden on healthcare systems, particularly in developed
countries [1]. Documentation of this impact at a global
level is complex, given the differences in health care sys-
tems, technology, coding methods and processes for mon-
itoring such diseases.
Fractures that arise from osteoporosis are a long-
recognised major cause of death and morbidity [2–4]. An
estimated 2·7 million hip fractures occurred in 2010 world-
wide [5]. In the EU, in the same year, 3.5 million new frac-
tures were estimated to have occurred, comprising approx-
imately 620,000 hip fractures, 520,000 vertebral fractures,
560,000 forearm fractures and 1,800,000 other fragility
fractures [6, 7]. The cost of osteoporosis, including pharma-
cological intervention in the EU, was estimated at €37 bil-
lion, with two-thirds derived from the treatment of incident
fractures and only 5% representing the costs of pharmaco-
logical prevention. The total cost including values of quality
adjusted life years (QALYs) lost was estimated at €98 bil-
lion, a figure that is expected to rise to €121 billion in 2025.
In the late 1990s, the World Health Organization (WHO)
drew attention to the need to formulate a global strategy for
the prevention and control of NCDs, including osteoporosis
[8]. The subsequent work of the then WHO Collaborating
Centre for Metabolic Bone Disease at the University of
Sheffield led to the development and launch in 2008 of a
freely available, fracture risk assessment tool (FRAX®,
www.shef.ac.uk/FRAX) [2]. The tool is used to generate
10-year probabilities of fracture at the hip or major skeletal
sites (hip, spine, humerus and distal forearm) using easily
captured clinical risk factors, with or without the addition of
femoral neck bone mineral density (BMD). FRAX has the
advantage of being a global health care tool and has been
widely adopted within clinical guidelines [9]. The current
tool provides risk calculators for 66 countries and territories
comprising well over 80% of the world population and is
available in 34 languages. A recent survey found that it had
been accessed from at least 228 countries or dependencies
worldwide, with the USA being the source of the highest
number of users [10]. As a global tool, the FRAX website
provides an excellent opportunity to explore the impact of
the COVID-19 pandemic on one aspect of care related to a
NCD with significant global impact, osteoporosis and its
related fracture burden.
Methods
For this retrospective, descriptive analysis, we assessed world-
wide and country/territory specific usage of the FRAX
website by examining the number of sessions of website ac-
tivity, and the geographical source of that activity, using
GoogleAnalytics (https://analytics.google.com/analytics/
web/). Briefly, GoogleAnalytics determines the user’s
location from their IP address and counts each visit as a
session. Currently, a session is defined as a group of
interactions with the website that any one user can make
within a 30-min time frame. The session number underesti-
mates fracture risk calculations as more than one calculation
can occur within the session. Data at the country level are
described as accurate worldwide; it is believed that access
via mobile devices or VPN can lead to inaccuracies in tracking
the source, but usually within the country of origin (e.g.
assigned to the wrong city).
A preliminary analysis of global FRAX access showed
that levels of usage were stable from November 2019 to
February 2020, so that we have restricted the main analysis
and presentation of usage data to the 3-month period,
February to April 2020, given that the WHO declared
COVID-19 a pandemic on 11 March 2020. In addition, we
undertook a visual comparison of FRAX access and usage
within the same period in 2019. Data were exported from
Google Analytics in XLSX format for further analysis. The
analysis focussed on the number of sessions accessed from
each country, and within each region/continent, in the
3 months of interest. For comparison across regions, the
average changes in sessions were weighted by the number
of sessions recorded in February within each country of the
particular region. Finally, the changes in FRAX usage were
correlated with markers of COVID-19 burden within each
country, using data from the Worldometer COVID-19 data-
base (https://www.worldometers.info/coronavirus/#
countries; accessed 9th May 2020); these comprised the
number of cases per million of the population, the number
of deaths per million and, finally, the number of COVID-
tests per million.
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Results
Global changes
The usages of the FRAX website for the periods of February–
April 2019 and 2020 are shown in Fig. 1. The session rate
remained constant throughout the observed period in 2019.
During the 3-month period, February to April 2020 inclusive,
the FRAX website recorded 460,495 sessions from 184 coun-
tries. The majority of these sessions (29.2%) arose from the
USA. In February alone, an absolute number of 210,656 sessions
were recorded, but this decreased to 161,986 in March and fell
further in April to 87,853 sessions, representing decreases of
23.1% and 58.3% respectively from the number captured in
February. As can be seen in Fig. 1 (top panel), the decrease in
global usage started around the middle of March, consistent with
the pandemic declaration, progressed during the second half of
the month and remained low throughout the month of April.
Of the 184 countries, 139 had access or usage data for all
3 months. In order to make meaningful comparisons across
countries, we confined further analysis to those countries with
at least 100 sessions recorded on the FRAX website in
February 2020. This cohort of 66 countries comprised
207,395 sessions in February, 159,466 sessions in March
and 86,351 in April, representing 98.5%, 98.4% and 98.3%
of the respective monthly totals. Results in terms of numbers
of sessions and percentage changes from February through to
April for all 66 individual countries are shown in
Supplementary Table S1. Of these 66 countries, 15 were from
Asia, 31 in Europe, 8 each in the Middle East/Africa (data
only for South Africa) and Latin America and 2 each in
North America and Oceania. The mean reductions in FRAX
sessions in each region for March and April compared with
February are shown in Table 1. A major difference was ob-
served in the changes in FRAX usage with apparently much
less marked reductions in Asia compared with Europe,Middle
Fig. 1 Daily number of sessions
recorded on the FRAX online
website during the months of
February, March and April 2020
(top panel) and 2019 (bottom
panel). The date of the declaration
of the pandemic is also shown on
the top panel. The cyclical pattern
reflects increased usage on
weekdays with lower usage at the
weekends
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East/Africa, Latin America and North America. Oceania
showed intermediate reductions.
Changes within regions
As expected, there was marked variability within each region
(Table 1; Supplementary Table S1). For example, in Latin
America, all 8 countries studied showed reductions greater
than 50%, with the smallest reduction seen in Brazil (−
54.5%) and the greatest seen in Ecuador (− 76.9%). Within
the Middle East/Africa region, only Qatar and Egypt showed
reductions of less than 50%, with Egypt showing a reduction
of only 26.0%.
In Europe, the majority of countries (24/31, 77.4%)
showed reductions of at least 50% between February and
April, with 6 of these (Spain, Portugal, Greece, Malta,
Georgia and Slovenia) showing decreases of more than
75%. The 7 countries showing smaller reductions included
Poland (− 2.85%), Slovakia (− 21.2%), the Czech Republic
(− 22.6%), Germany (− 26.9%), Norway (− 31.7%), Sweden
(− 41.4%) and Finland (− 44.1%) (Fig. 2).
In North America, proportional decreases in usage by April
were greater for the USA than for Canada (− 60.9% and −
44.9% respectively). In Oceania, whilst the decreases in
March were similar between New Zealand and Australia, the
decrease observed between April and February was two-fold
higher for New Zealand than for Australia (− 64.5% vs −
31.4% respectively).
The discordance in apparent changes was most marked in
Asia (Supplementary Table S1). Here, only 4 countries (4/15,
26.7%) showed reductions of 50% or more in April compared
with February; these comprised Thailand (− 52.1%), India (−
57.0%), the Philippines (− 78.9%) and Pakistan (− 63.6%).
Intriguingly, 5 countries (33.3%) in the region showed an
increase in FRAX sessions between February and April;
Asia was the only region in which this occurred. The relevant
countries/territories were Taiwan (+4.0%), Hong Kong
(+23.5%), South Korea (+35.3%), China (+51.7%) and
Vietnam (+232.8%). Subsequent analysis in these countries
over a longer time frame, from the end of November 2019
until the end of April 2020, showed that the apparent improve-
ment in FRAX usage had been preceded by earlier declines in
FRAX session number (Fig. 3; Supplementary Figure S1).
When expressed as sessions per month, the nadir for China
and Taiwan occurred in January (− 39.9% and − 33.9% re-
spectively, compared with November 2019), with nadirs for
the other 3 countries occurring in February 2020 (− 56.4%, −
44.9% and − 32.6% for Vietnam, Hong Kong and South
Korea respectively).
Relationship of reduction in FRAX usage with markers
of COVID-19 burden
There were very weak, non-statistically significant correla-
tions between the impact of COVID-19 (cases, deaths and
tests per million of the population) on FRAX usage, as judged
by the reduction in usage between February and April. For the
three measures, the correlation coefficients were 0.22 (p =
0.076), 0.21 (p = 0.09) and 0.20 (p = 0.112) respectively.
Discussion
The direct impact of SARS-CoV-2 infection and the COVID-
19 pandemic on morbidity, mortality and healthcare resource
use across the globe has rightly been the focus of much re-
search. NCDs have also featured prominently given the inter-
action between underlying health conditions and the likeli-
hood of adverse outcomes during the infection [11–13].
Perhaps less frequently, but no less importantly, some have
drawn attention to the detrimental impact that the focus on
COVID-19 will have on the medium to long term manage-
ment and outcomes for many common NCDs [14–17]. The
present analysis is perhaps the first to quantify a very marked
effect of the pandemic to reduce the assessment of fracture
risk, a key component in the targeted initiation of preventative
treatment to reduce the future burden of fractures. The reduc-
tion is substantial, averaging 58% but ranging up to 96%, and
is truly global with two-thirds of the 66 countries/territories
evaluated showing reductions by at least 50%.
Table 1 Percentage changes in
online FRAX usage (sessions) for
the 6 regions shown. The
percentages were weighted by
FRAX usage for each country
within each region. The numbers
in parentheses represent the range
(minimum, maximum) of
changes for countries within the
region
Percentage (%) decrease from February
Region Countries (N) March April
Asia 15 − 7.6 (− 38.3, + 23.4) − 14.4 (− 78.9, + 232.8)
Europe 31 − 27.7 (− 74.5, + 17.4) − 64.6 (− 96.5, − 2.85)
Latin America 8 − 16.7 (− 30.2, + 1.6) − 61.4 (− 76.9, − 54.5)
Middle East/Africa 8 − 34.5 (− 44.9, − 11.6) − 67.5 (− 84.3, − 26.0)
North America 2 − 22.0 (− 22.6, − 16.7) − 59.0 (− 60.9, − 44.9)
Oceania 2 − 10.4 (− 13.1, − 9.0) − 42.2 (− 64.5, − 31.4)
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The detrimental effect of the pandemic on osteoporosis and
fracture risk is not only confined to a reduction in risk assess-
ment [18]. Access to osteoporosis treatments that often require
direct medical contact, such as intravenous or subcutaneous
antiresorptives, are likely to be delayed or missed, raising the
risk of further fracture particularly in the case of subcutaneous
denosumab [19]. The opportunity provided by face-to-face
contact via Fracture Liaison Services, at the time of or shortly
after an incident fracture, or bone density services, to initiate
treatment has more or less halted as secondary care has been
diverted to COVID-19 care, or the risk of infection has been
deemed too high. Furthermore, measures applied at city, re-
gional and national levels around self-isolation and social dis-
tancing may well reduce exercise exposure and impair general
Fig. 2 Map of Europe showing the reduction in FRAX usage between February and April 2020. Countries shown in white were not included in the
analysis
Fig. 3 Weekly FRAX session numbers (expressed as a percentage of baseline values calculated from usage in November 2019) betweenDecember 2019
and April 2020 in the countries shown
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health with a consequent increase in physical frailty, falls and
related fractures.
The variation in reduction in FRAX usage is marked, and
the reasons for this are likely to be complex. The most obvious
observation is that the reduction in FRAX usage was much
less marked in Asia than in other regions. The early and rapid
response of China and its neighbouring countries/territories to
the threat posed by SARS-CoV-2 has been much discussed.
China itself commenced a mass quarantine of the city of
Wuhan, the epicentre of the viral outbreak, on 23 January
and the WHO declared the infection as a Public Health
Emergency of International Concern (PHEIC) on 30
January. The close geographical proximity, lessons learned
from the previous SARS and Middle East Respiratory
Syndrome (MERS) pandemics in 2002 and 2015 respectively,
and subsequent infrastructure investments, meant that an early
combination of identification (based on symptoms or antigen
testing), containment and contact tracing appeared to limit the
spread of the disease and its impact on general healthcare. It is
notable that the use of FRAX within the immediate region
decreased but recovered quickly, suggesting that the measures
capped the infection rate early before it overwhelmed the
healthcare systems. In other Asian countries, for example in
the Philippines, like many countries in Europe and beyond
where some of the impacts have been substantial, the onset
of action was delayed and occurred around the time of, or
within days of, the declaration of a pandemic by WHO on
March 11th. Our analysis notes an association between the
later onset of measures to contain the outbreak and an appar-
ently longer duration of suppression of FRAX access; the
reasons for this are again likely to be complex, need further
exploration and are beyond the scope of this report. For ex-
ample, within Europe, the decrease in FRAX access in Poland
appears to have been short lived, despite adopting apparently
similar measures to neighbouring countries; the cause of this
is unclear. However, what is clear is that the pandemic is
having a significant impact on the management of a chronic
NCD such as osteoporosis.
Our study has a number of limitations and strengths. The
metric captured by GoogleAnalytics is sessions rather than
individual calculations and is an underestimate of the latter.
Over the 1-month period of April, there were approximately
123,000 fewer FRAX sessions than might have been expect-
ed. Bearing in mind that the session number underestimates
the actual number of FRAX calculations by about 30% [20],
then somewhere in the region of 175,000 patients were likely
excluded from fracture risk assessment. If the measures
adopted to address COVID-19 continue to impede osteoporo-
sis care, then over a 3-month period more than 0.5 million
patients would be excluded from assessment and a substantial
proportion of those from necessary treatment. This is also an
underestimate as many of the FRAX assessments worldwide
are conducted on bone densitometers rather than through the
web, activity which has largely ceased in many countries. As
recognised by many, by the time this pandemic is over, a
major challenge will remain to address and cope with the
consequences of a huge backlog of NCDs. A major strength
is that the study utilises a single metric captured via a single
portal, the online FRAX fracture risk assessment tool, to com-
pare the changes across countries with time. This contrasts
with cross-country comparisons of, for example, the number
of COVID-19 cases as the latter depends on political and
healthcare policy and resources, and the integrity of mecha-
nisms to categorise and count. The latter may have impacted
on our attempts to correlate changes in FRAX usage with
measures of COVID-19 burden.
Having observed and quantified the impact of the pan-
demic on a marker of NCD management, a number of
questions arise, the most obvious one being how do we
address the increasing backlog of these “non-essential”
diseases in the short and longer term? We cannot simply
ignore the fact that 71% of global mortality in 2016 was
due to NCDs [21]. Within the field of osteoporosis, one
potential answer lies with the FRAX tool itself. Many
studies have examined its clinical utility since its launch
in 2008; two systematic reviews have demonstrated the
significant predictive ability of FRAX for future fractures,
especially of the hip [22, 23]. In general, the incorporation
of a measurement of femoral neck BMD results in higher
accuracy than without BMD, but the additional value of
BMD in all is modest [24]. It should also be recognised
that even if the performance of FRAX is enhanced by the
use of BMD tests, FRAX without BMD has a predictive
value for fractures that is comparable to the use of BMD
alone [25]. Several analyses have shown that patients
identified at high risk of fracture by FRAX are responsive
to osteoporosis treatments, including the recent study of
screening by FRAX in the UK [26–29]. The availability
and access to densitometry in many countries is low and
access to largely secondary care-based facilities are fur-
ther compromised or inhibited completely during the cur-
rent pandemic [17]. Catching up with the backlog would
be much enhanced by the assessment of fracture risk by
FRAX in the absence of BMD in many patients, with the
use of limited BMD resources targeted to those lying at or
near intervention thresholds [24, 30]. The final major ad-
vantage in the current setting is that the assessment with
FRAX can be undertaken remotely via telemedicine; in-
deed, future approaches could include embedding the
FRAX risk assessment within electronic primary care
records.
In summary, this analysis quantifies the impact of the
COVID-19 pandemic and different approaches to its manage-
ment on fracture risk assessment by the online FRAX tool. In
many countries, the impact is large and persisting and it is
highly likely that similar patterns are seen across many
Osteoporos Int
NCDs. Though not studied directly here, preparedness is like-
ly to be one of the major drivers limiting the impact. Many
lessons need to be learned for future national and international
events impacting on health care resources.
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